1. 1st Department of Medicine, Charles University General Hospital, Prague, Czech Republic;
2. Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic;
3. Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland;
4. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
5. The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada;
6. Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy;
7. Department of Hematology, The First Affiliated Hospital of Zheijiang University College of Medicine, Zheijiang, China;
8. Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
9. Department of Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada;
10. AOU Citta’ Della Salute e della Scienza, SC Ematologia, Turin, Italy;
11. SC Ematologia, Azienda Sanitaria Universitaria Integrata, Trieste, Italy;
12. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China;
13. Pharma Development Biometrics Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland;
14. Oncology Biomarker Development and
15. Bioinformatics, Genentech Inc., South San Francisco, CA; and
16. Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland